Tags

Type your tag names separated by a space and hit enter

Allopurinol attenuates L-NAME induced cardiomyopathy comparable to blockade of angiotensin receptor.
Histol Histopathol. 2008 10; 23(10):1241-8.HH

Abstract

It is widely recognized that L-NAME exposed rats develop myocardial fibrosis and hypertrophy. The aim of this study was to evaluate the contribution of xanthine oxidase (XO) to these phenomena using allopurinol, isolated or associated with olmesartan. Thirty adult male Wistar rats were divided into 5 groups (n=6) and studied for 5 weeks: L group (L-NAME, 40mg/kg/day); L+A group (L-NAME and allopurinol, 40 mg/kg/day); L+O group (L-NAME and olmesartan, 15mg/kg/day); L+A+O group (L-NAME, allopurinol, and olmesartan); and control group. L-NAME caused arterial hypertension and cardiomyocyte hypertrophy. Hypertension was prevented by olmesartan, but not by allopurinol. There was an increase of left ventricular mass index in the L-NAME group that was prevented by allopurinol, olmesartan and by the combination of both. The increase in mean cardiomyocyte transversal area caused by L-NAME was prevented by the allopurinol and olmesartan combination, or by olmesartan used as monotherapy, but not by allopurinol alone. There was a reduction in the myocardial vascularization index caused by L-NAME which was abolished by allopurinol or by olmesartan, but not by the association. L-NAME caused a reduction in the total number of cardiomyocyte nuclei. This was prevented by olmesartan alone or associated with allopurinol, but not by allopurinol alone. We conclude that XO has an important contribution to adverse cardiac remodeling in L-NAME exposed animals. Moreover, allopurinol acts without interfering with L-NAME induced hypertension. The protective action of this drug is comparable to the results obtained with olmesartan. Antioxidative mechanisms are proposed to account for the pressure independent effects of allopurinol.

Authors+Show Affiliations

Laboratory of Morphometry and Cardiovascular Morphology, Biomedical Center, Institute of Biology, Rio de Janeiro, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18712676

Citation

Kasal, D A B., et al. "Allopurinol Attenuates L-NAME Induced Cardiomyopathy Comparable to Blockade of Angiotensin Receptor." Histology and Histopathology, vol. 23, no. 10, 2008, pp. 1241-8.
Kasal DA, Neves MF, Oigman W, et al. Allopurinol attenuates L-NAME induced cardiomyopathy comparable to blockade of angiotensin receptor. Histol Histopathol. 2008;23(10):1241-8.
Kasal, D. A., Neves, M. F., Oigman, W., & Mandarim-de-Lacerda, C. A. (2008). Allopurinol attenuates L-NAME induced cardiomyopathy comparable to blockade of angiotensin receptor. Histology and Histopathology, 23(10), 1241-8. https://doi.org/10.14670/HH-23.1241
Kasal DA, et al. Allopurinol Attenuates L-NAME Induced Cardiomyopathy Comparable to Blockade of Angiotensin Receptor. Histol Histopathol. 2008;23(10):1241-8. PubMed PMID: 18712676.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Allopurinol attenuates L-NAME induced cardiomyopathy comparable to blockade of angiotensin receptor. AU - Kasal,D A B, AU - Neves,M F, AU - Oigman,W, AU - Mandarim-de-Lacerda,C A, PY - 2008/8/21/pubmed PY - 2008/10/24/medline PY - 2008/8/21/entrez SP - 1241 EP - 8 JF - Histology and histopathology JO - Histol Histopathol VL - 23 IS - 10 N2 - It is widely recognized that L-NAME exposed rats develop myocardial fibrosis and hypertrophy. The aim of this study was to evaluate the contribution of xanthine oxidase (XO) to these phenomena using allopurinol, isolated or associated with olmesartan. Thirty adult male Wistar rats were divided into 5 groups (n=6) and studied for 5 weeks: L group (L-NAME, 40mg/kg/day); L+A group (L-NAME and allopurinol, 40 mg/kg/day); L+O group (L-NAME and olmesartan, 15mg/kg/day); L+A+O group (L-NAME, allopurinol, and olmesartan); and control group. L-NAME caused arterial hypertension and cardiomyocyte hypertrophy. Hypertension was prevented by olmesartan, but not by allopurinol. There was an increase of left ventricular mass index in the L-NAME group that was prevented by allopurinol, olmesartan and by the combination of both. The increase in mean cardiomyocyte transversal area caused by L-NAME was prevented by the allopurinol and olmesartan combination, or by olmesartan used as monotherapy, but not by allopurinol alone. There was a reduction in the myocardial vascularization index caused by L-NAME which was abolished by allopurinol or by olmesartan, but not by the association. L-NAME caused a reduction in the total number of cardiomyocyte nuclei. This was prevented by olmesartan alone or associated with allopurinol, but not by allopurinol alone. We conclude that XO has an important contribution to adverse cardiac remodeling in L-NAME exposed animals. Moreover, allopurinol acts without interfering with L-NAME induced hypertension. The protective action of this drug is comparable to the results obtained with olmesartan. Antioxidative mechanisms are proposed to account for the pressure independent effects of allopurinol. SN - 1699-5848 UR - https://www.unboundmedicine.com/medline/citation/18712676/Allopurinol_attenuates_L_NAME_induced_cardiomyopathy_comparable_to_blockade_of_angiotensin_receptor_ L2 - http://www.hh.um.es/Abstracts/Vol_23/23_10/23_10_1241.htm DB - PRIME DP - Unbound Medicine ER -